Loading
Cancer-seeking molecules carrying the radioactive metal lutetium-177, which delivers short-range radiation to tumours it binds; approved for neuroendocrine tumours and prostate cancer.
Lutetium-177 emits beta particles with a range of a few millimetres and gamma rays that allow imaging, making it the workhorse isotope of radioligand therapy. Lutathera (Lu-177 dotatate, approved 2018) targets somatostatin receptors on neuroendocrine tumours, and Pluvicto (Lu-177 PSMA-617, approved 2022) targets PSMA on prostate cancer; both improved outcomes in randomised trials. Supply of no-carrier-added lutetium, dosimetry and combinations with earlier lines of therapy are the current frontiers.
A peptide or small molecule with high affinity for a tumour receptor is chelated to Lu-177 and infused; bound molecules irradiate the cell and its neighbours over the isotope's 6.6-day half-life.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Query for this technology: (TITLE:"Lutetium-177 radioligand therapy" OR ABSTRACT:"Lutetium-177 radioligand therapy" OR TITLE:"177Lu" OR ABSTRACT:"177Lu" OR TITLE:"Lu-177" OR ABSTRACT:"Lu-177" OR TITLE:"Lutetium-177" OR ABSTRACT:"Lutetium-177") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Lutetium-177 radioligand therapy, not a curated reading list.
Shares Somatostatin receptor 2, PSMA, Radioligand therapy (beta emitters), Neuroendocrine tumours.
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA, Radioligand therapy (beta emitters).
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA.
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA.
Shares Radioligand dosimetry, Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan.
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Neuroendocrine tumours.
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Radioligand therapy (beta emitters), Neuroendocrine tumours.
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Radioligand therapy (beta emitters), Neuroendocrine tumours.